QNASL FDA Approval History
FDA Approved: Yes (First approved March 23, 2012)
Brand name: QNASL
Generic name: beclomethasone dipropionate
Dosage form: Nasal Aerosol
Company: Teva Pharmaceutical Industries Ltd.
Treatment for: Allergic Rhinitis
QNASL (beclomethasone dipropionate) is an intranasal corticosteroid non-aqueous "dry" spray formulation for the treatment of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR).
Development Timeline for QNASL
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.